Patient Stories Needed to Share With The FDA

Cure Our Ovarian CancerNews

Cure Our Ovarian Cancer is supporting STAAR Ovarian Cancer’s efforts to improve recognition and understanding of low-grade serous ovarian cancer at a drug regulatory level.

In October STAAR Ovarian Cancer will be hosting a virtual Patient-Focused Drug Development Meeting. The meeting is an important opportunity for the U.S. Food and Drug Administration to hear first-hand from people affected by low-grade serous ovarian cancer.

There are currently no FDA approved treatments that have been specifically approved for low-grade serous ovarian cancer. Cure Our Ovarian Cancer believes this meeting will reduce barriers for the approval of low-grade serous specific treatments in the future.

In preparation for the meeting STAAR Ovarian Cancer needs to gather as many stories from people living with low-grade serous cancer from around the world. We would like to encourage as many people to participate as possible.

To learn more about the Patient-Focused Drug Development Meeting and share your story please visit:

STAAR Ovarian Cancer is Cure Our Ovarian Cancer’s American Low-Grade Serous Charity Research Partner. As the only dedicated low-grade serous ovarian cancer charity in the United States, STAAR Ovarian Cancer funds impactful research to improve the survival of women with low-grade serous cancer.